Comparing Mycophenolate Mofetil vs Prograf
| Mycophenolate mofetil | Prograf |
|
|---|
| Mycophenolate mofetil | Prograf tacrolimus |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescribed for Nephrotic Syndrome, Organ Transplant - Rejection Prophylaxis, Graft-versus-host disease. May also be prescribed off label for Bullous Pemphigoid, Autoimmune Hepatitis, Crohn's Disease... View more |
Prescribed for Organ Transplant - Rejection Prophylaxis, Organ Transplant - Rejection Reversal. Prograf may also be used for purposes not listed in this medication guide. |
Choose a suggestion below Organ Transplant, Rejection Prophylaxis
|
|||||||||||||||
| More about Mycophenolate mofetil | More about Prograf (tacrolimus) | ||||||||||||||||
| Generic Status | |||||||||||||||||
| Availability | |||||||||||||||||
|
Prescription only |
Prescription only |
||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Mycophenolate mofetil has an average rating of 8.0 out of 10 from a total of 53 ratings on Drugs.com. 72% of reviewers reported a positive effect, while 9% reported a negative effect. |
Prograf has an average rating of 8.0 out of 10 from a total of 27 ratings on Drugs.com. 79% of reviewers reported a positive effect, while 8% reported a negative effect. |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Side Effects | |||||||||||||||||
|
Commonly reported side effects include: asthma, herpes simplex infection, infection, metabolic acidosis, oral candidiasis, pleural effusion, respiratory tract infection, systemic cytomegalovirus disease, urinary tract infection, viremia, abdominal pain, acne vulgaris, anemia, anxiety, asthenia, back pain, cardiovascular disorder, chest pain, constipation, cough, depression, diarrhea, disorder of integument, drowsiness, dyspepsia, dyspnea, edema, fever, headache, hypercholesterolemia, hyperlipidemia, hypertension, hypertonia, hyperuricemia, hypervolemia, hypokalemia, hypotension, increased lactate dehydrogenase, increased serum alanine aminotransferase, increased serum aspartate aminotransferase, increased serum creatinine, leukopenia, lower limb cramp, myalgia, myasthenia, nausea, pain, paresthesia, peripheral edema, pulmonary disease, rhinitis, sinusitis, tachycardia, thrombocytopenia, tremor, vomiting, weight gain, chills, and flatulence. See the full mycophenolate mofetil side effects document. |
Common side effects include: opportunistic infection, diabetes mellitus, infection, headache, hyperglycemia, hyperkalemia, increased blood urea nitrogen, increased serum creatinine, mental status changes, nephrotoxicity, sensation disorder, and tremor. See the full Prograf side effects document. |
||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all mycophenolate mofetil prices |
View all Prograf prices and generic prices |
||||||||||||||||
| Dosage Form(s) Available | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
| CellCept | Other tacrolimus brands include: Astagraf XL, Envarsus XR | ||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | |||||||||||||||||
|
18 hours |
21.2 hours |
||||||||||||||||
| CSA Schedule** View glossary of terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Category D
Positive evidence of risk
See the full Pregnancy Warnings document. |
Category C
Risk cannot be ruled out
See the full Pregnancy Warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 298 drugs are known to interact with mycophenolate mofetil:
|
A total of 775 drugs are known to interact with Prograf:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
May 03, 1995 |
April 08, 1994 |
||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
|
|||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.